

1010-0001 PCT/ATO 1-0 JAN 2002

FORM PT-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

RTSP-0234

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

10/049743

INTERNATIONAL APPLICATION NO

PCT/US00/00525

INTERNATIONAL FILING DATE

6 January 2000

PRIORITY DATE CLAIMED

19 July 1999

TITLE OF INVENTION

ANTISENSE MODULATION OF P13 KINASE P110 DELTA EXPRESSION

APPLICANT(S) FOR DO/EO/US

MONIA, Brett P. and COWSERT, Lex M.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter 2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

1) Courtesy copy of the International Application; 2) Statement to support filing and submission in accordance with 37 CFR 1.821-1.825; 3) Paper and disk copy of Amended Sequence Listing; 4) Return post card.

U.S. APPLICATION NO. (IF KNOWN) SEE 37 CFR 1.53 10/049743		INTERNATIONAL APPLICATION NO. PCT/US00/00525		ATTORNEY'S DOCKET NUMBER RTSP-0234	
---	--	--	--	--	--

24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$1040.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$890.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$740.00	
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$710.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$710.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	19 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$84.00	\$0.00	
Multiple Dependent Claims (check if applicable).				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$710.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$355.00	
SUBTOTAL =				\$355.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$355.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				\$0.00	
TOTAL FEES ENCLOSED =				\$355.00	
				Amount to be:	\$
				refunded	
				charged	\$

a. ☒ A check in the amount of **\$355.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-1619**. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Registration No. 32,257
 Kathleen A. Tyrrell, Registration No. 38,350
 Licata & Tyrrell P.C.
 66 East Main Street
 Marlton, New Jersey 08053

Tel: 856-810-1515
 Fax: 856-810-1454

Jane Massey Licata
 SIGNATURE

Jane Massey Licata
 NAME

32,257
 REGISTRATION NUMBER

January 10, 2002
 DATE

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05958 A1

- (51) International Patent Classification⁷: C12N 15/00, 15/11, C12Q 1/68, A61K 48/00
- (74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: PCT/US00/00525
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 6 January 2000 (06.01.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/357,070 19 July 1999 (19.07.1999) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MONIA, Brett, P. [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). COWSERT, Lex, M. [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).
- Published:**
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/05958 A1

(54) Title: ANTISENSE MODULATION OF P13 KINASE P110 DELTA EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of P13 kinase p110 delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding P13 kinase p110 delta. Methods of using these compounds for modulation of P13 kinase p110 delta expression and for treatment of diseases associated with expression of P13 kinase p110 delta are provided.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/00525**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 15/00, 15/11; C12Q 1/68; A61K 48/00

US CL : 435/6, 366, 375, 91.1; 536/23.1, 24.3, 24.5; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 366, 375, 91.1; 536/23.1, 24.3, 24.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE, BIOSIS, WEST1.1A**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HOOVER et al. Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase. J. of Medicinal Chemistry. 30 July 1998, Vol. 41, No. 16, pages 2934-2938, especially page 2934.	1



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents

"A"

document defining the general state of the art which is not considered to be of particular relevance

"E"

earlier document published on or after the international filing date

"L"

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O"

document referring to an oral disclosure, use, exhibition or other means

"P"

document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

13 MARCH 2000

Date of mailing of the international search report

15 MAY 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARY SCHMIDT

Telephone No. (703) 308-0196

#3/a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0234
Inventors: Monia and Cowsert
Serial No.: Not yet assigned
Filing Date: Herewith
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: ANTISENSE MODULATION P13 KINASE P110
DELTA EXPRESSION

"Express Mail" Label No. EV 017478038 US
Date of Deposit January 10, 2002

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Assistant Commissioner for Patents, Washington,
D.C. 20231.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

It is respectfully requested that the Sequence Listing of the
instant specification be deleted and replaced with the amended
Sequence Listing provided herewith. A paper copy and a CRF copy of
the amended Sequence Listing are provided herewith.

The replacement Sequence Listing has been amended to conform
with the current Sequence Listing Rules.

Attorney Docket No.: RTSP-0234
Inventors: Monia and Cowsert
Serial No.: Not yet assigned
Filing Date: Herewith
Page 2

No new matter has been added by this amendment.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: January 10, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

1

SEQUENCE LISTING

<110> Brett P. Monia
Lex M. Cowsert

<120> ANTISENSE MODULATION OF PI3 KINASE P110 DELTA EXPRESSION

<130> RTSP-0234

<140>

<141>

<150> US 09/357,070

<151> 1999-07-19

<160> 47

<210> 1

<211> 3868

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (197)..(3331)

<400> 1

```

gaattcggca cgagcggccg cgagcagagc cgcccagccc tgccagctgc gccgggacga      60
taaggagtca ggccagggcg ggatgacact cattgattct aaagcatctt taatctgccca    120
ggcggagggg gctttgctgg tctttcttgg actattccag agaggacaac tgtcatctgg    180
gaagtaacaa cgcagg atg ccc cct ggg gtg gac tgc ccc atg gaa ttc      229
                Met Pro Pro Gly Val Asp Cys Pro Met Glu Phe
                  1                5                10

tgg acc aag gag gag aat cag agc gtt gtg gtt gac ttc ctg ctg ccc      277
Trp Thr Lys Glu Asn Gln Ser Val Val Val Asp Phe Leu Leu Pro
                15                20                25

aca ggg gtc tac ctg aac ttc cct gtg tcc cgc aat gcc aac ctc agc      325
Thr Gly Val Tyr Leu Asn Phe Pro Val Ser Arg Asn Ala Asn Leu Ser
                30                35                40

acc atc aag cag ctg ctg tgg cac cgc gcc cag tat gag ccg ctc ttc      373
Thr Ile Lys Gln Leu Leu Trp His Arg Ala Gln Tyr Glu Pro Leu Phe
                45                50                55

cac atg ctc agt ggc ccc gag gcc tat gtg ttc acc tgc atc aac cag      421
His Met Leu Ser Gly Pro Glu Ala Tyr Val Phe Thr Cys Ile Asn Gln
                60                65                70                75

aca gcg gag cag caa gag ctg gag gac gag caa cgg cgt ctg tgt gac      469
Thr Ala Glu Gln Gln Glu Leu Glu Asp Glu Gln Arg Arg Leu Cys Asp
                80                85                90

gtg cag ccc ttc ctg ccc gtc ctg cgc ctg gtg gcc cgt gag ggc gac      517
Val Gln Pro Phe Leu Pro Val Leu Arg Leu Val Ala Arg Glu Gly Asp

```

	95	100	105	
	cgc gtg aag aag ctc atc aac tca cag atc agc ctc ctc atc ggc aaa			565
	Arg Val Lys Lys Leu Ile Asn Ser Gln Ile Ser Leu Leu Ile Gly Lys			
	110	115	120	
	ggc ctc cac gag ttt gac tcc ttg tgc gac cca gaa gtg aac gac ttt			613
	Gly Leu His Glu Phe Asp Ser Leu Cys Asp Pro Glu Val Asn Asp Phe			
	125	130	135	
	cgc gcc aag atg tgc caa ttc tgc gag gag gcg gcc gcc cgc cgg cag			661
	Arg Ala Lys Met Cys Gln Phe Cys Glu Glu Ala Ala Ala Arg Arg Gln			
	140	145	150	155
	cag ctg ggc tgg gag gcc tgg ctg cag tac agt ttc ccc ctg cag ctg			709
	Gln Leu Gly Trp Glu Ala Trp Leu Gln Tyr Ser Phe Pro Leu Gln Leu			
	160	165	170	
	gag ccc tcg gct caa acc tgg ggg cct ggt acc ctg cgg ctc ccg aac			757
	Glu Pro Ser Ala Gln Thr Trp Gly Pro Gly Thr Leu Arg Leu Pro Asn			
	175	180	185	
	cgg gcc ctt ctg gtc aac gtt aag ttt gag ggc agc gag gag agc ttc			805
	Arg Ala Leu Leu Val Asn Val Lys Phe Glu Gly Ser Glu Glu Ser Phe			
	190	195	200	
	acc ttc cag gtg tcc acc aag gac gtg ccg ctg gcg ctg atg gcc tgt			853
	Thr Phe Gln Val Ser Thr Lys Asp Val Pro Leu Ala Leu Met Ala Cys			
	205	210	215	
	gcc ctg cgg aag aag gcc aca gtg ttc cgg cag ccg ctg gtg gag cag			901
	Ala Leu Arg Lys Lys Ala Thr Val Phe Arg Gln Pro Leu Val Glu Gln			
	220	225	230	235
	ccg gaa gac tac acg ctg cag gtg aac ggc agg cat gag tac ctg tat			949
	Pro Glu Asp Tyr Thr Leu Gln Val Asn Gly Arg His Glu Tyr Leu Tyr			
	240	245	250	
	ggc agc tac ccg ctc tgc cag ttc cag tac atc tgc agc tgc ctg cac			997
	Gly Ser Tyr Pro Leu Cys Gln Phe Gln Tyr Ile Cys Ser Cys Leu His			
	255	260	265	
	agt ggg ttg acc cct cac ctg acc atg gtc cat tcc tcc tcc atc ctc			1045
	Ser Gly Leu Thr Pro His Leu Thr Met Val His Ser Ser Ser Ile Leu			
	270	275	280	
	gcc atg cgg gat gag cag agc aac cct gcc ccc cag gtc cag aaa ccg			1093
	Ala Met Arg Asp Glu Gln Ser Asn Pro Ala Pro Gln Val Gln Lys Pro			
	285	290	295	
	cgt gcc aaa cca cct ccc att cct gcg aag aag cct tcc tct gtg tcc			1141
	Arg Ala Lys Pro Pro Pro Ile Pro Ala Lys Lys Pro Ser Ser Val Ser			
	300	305	310	315
	ctg tgg tcc ctg gag cag ccg ttc cgc atc gag ctc atc cag ggc agc			1189
	Leu Trp Ser Leu Glu Gln Pro Phe Arg Ile Glu Leu Ile Gln Gly Ser			
	320	325	330	

aaa gtg aac gcc gac gag cgg atg aag ctg gtg gtg cag gcc ggg ctt	1237
Lys Val Asn Ala Asp Glu Arg Met Lys Leu Val Val Gln Ala Gly Leu	
335 340 345	
ttc cac ggc aac gag atg ctg tgc aag acg gtg tcc agc tcg gag gtg	1285
Phe His Gly Asn Glu Met Leu Cys Lys Thr Val Ser Ser Ser Glu Val	
350 355 360	
agc gtg tgc tcg gag ccc gtg tgg aag cag cgg ctg gag ttc gac atc	1333
Ser Val Cys Ser Glu Pro Val Trp Lys Gln Arg Leu Glu Phe Asp Ile	
365 370 375	
aac atc tgc gac ctg ccc cgc atg gcc cgt ctc tgc ttt gcg ctg tac	1381
Asn Ile Cys Asp Leu Pro Arg Met Ala Arg Leu Cys Phe Ala Leu Tyr	
380 385 390 395	
gcc gtg atc gag aaa gcc aag aag gct cgc tcc acc aag aag aag tcc	1429
Ala Val Ile Glu Lys Ala Lys Lys Ala Arg Ser Thr Lys Lys Lys Ser	
400 405 410	
aag aag gcg gac tgc ccc att gcc tgg gcc aac ctc atg ctg ttt gac	1477
Lys Lys Ala Asp Cys Pro Ile Ala Trp Ala Asn Leu Met Leu Phe Asp	
415 420 425	
tac aag gac cag ctt aag acc ggg gaa cgc tgc ctc tac atg tgg ccc	1525
Tyr Lys Asp Gln Leu Lys Thr Gly Glu Arg Cys Leu Tyr Met Trp Pro	
430 435 440	
tcc gtc cca gat gag aag ggc gag ctg ctg aac ccc acg ggc act gtg	1573
Ser Val Pro Asp Glu Lys Gly Glu Leu Leu Asn Pro Thr Gly Thr Val	
445 450 455	
cgc agt aac ccc aac acg gat agc gcc gct gcc ctg ctc atc tgc ctg	1621
Arg Ser Asn Pro Asn Thr Asp Ser Ala Ala Ala Leu Leu Ile Cys Leu	
460 465 470 475	
ccc gag gtg gcc ccg cac ccc gtg tac tac ccc gcc ctg gag aag atc	1669
Pro Glu Val Ala Pro His Pro Val Tyr Tyr Pro Ala Leu Glu Lys Ile	
480 485 490	
ttg gag ctg ggg cga cac agc gag tgt gtg cat gtc acc gag gag gag	1717
Leu Glu Leu Gly Arg His Ser Glu Cys Val His Val Thr Glu Glu Glu	
495 500 505	
cag ctg cag ctg cgg gaa atc ctg gag cgg cgg ggg tct ggg gag ctg	1765
Gln Leu Gln Leu Arg Glu Ile Leu Glu Arg Arg Gly Ser Gly Glu Leu	
510 515 520	
tat gag cac gag aag gac ctg gtg tgg aag ctg cgg cat gaa gtc cag	1813
Tyr Glu His Glu Lys Asp Leu Val Trp Lys Leu Arg His Glu Val Gln	
525 530 535	
gag cac ttc ccg gag gcg cta gcc cgg ctg ctg ctg gtc acc aag tgg	1861
Glu His Phe Pro Glu Ala Leu Ala Arg Leu Leu Leu Val Thr Lys Trp	
540 545 550 555	
aac aag cat gag gat gtg gcc cag atg ctc tac ctg ctg tgc tcc tgg	1909
Asn Lys His Glu Asp Val Ala Gln Met Leu Tyr Leu Leu Cys Ser Trp	
560 565 570	

cgc gag ctg ccc gtc ctg agc gcc ctg gag ctg cta gac ttc agc ttc	1957
Pro Glu Leu Pro Val Leu Ser Ala Leu Glu Leu Leu Asp Phe Ser Phe	
575 580 585	
ccc gat tgc cac gta ggc tcc ttc gcc atc aag tgc ctg cgg aaa ctg	2005
Pro Asp Cys His Val Gly Ser Phe Ala Ile Lys Ser Leu Arg Lys Leu	
590 595 600	
acg gac gat gag ctg ttc cag tac ctg ctg cag ctg gtg cag gtg ctc	2053
Thr Asp Asp Glu Leu Phe Gln Tyr Leu Leu Gln Leu Val Gln Val Leu	
605 610 615	
aag tac gag tcc tac ctg gac tgc gag ctg acc aaa ttc ctg ctg gac	2101
Lys Tyr Glu Ser Tyr Leu Asp Cys Glu Leu Thr Lys Phe Leu Leu Asp	
620 625 630 635	
cgg gcc ctg gcc aac cgc aag atc ggc cac ttc ctt ttc tgg cac ctc	2149
Arg Ala Leu Ala Asn Arg Lys Ile Gly His Phe Leu Phe Trp His Leu	
640 645 650	
cgc tcc gag atg cac gtg cgc tgc gtg gcc ctg cgc ttc ggc ctc atc	2197
Arg Ser Glu Met His Val Pro Ser Val Ala Leu Arg Phe Gly Leu Ile	
655 660 665	
ctg gag gcc tac tgc agg ggc agg acc cac cac atg aag gtg ctg atg	2245
Leu Glu Ala Tyr Cys Arg Gly Arg Thr His His Met Lys Val Leu Met	
670 675 680	
aag cag ggg gaa gca ctg agc aaa ctg aag gcc ctg aat gac ttc gtc	2293
Lys Gln Gly Glu Ala Leu Ser Lys Leu Lys Ala Leu Asn Asp Phe Val	
685 690 695	
aag ctg agc tct cag aag acc ccc aag ccc cag acc aag gag ctg atg	2341
Lys Leu Ser Ser Gln Lys Thr Pro Lys Pro Gln Thr Lys Glu Leu Met	
700 705 710 715	
cac ttg tgc atg cgg cag gag gcc tac cta gag gcc ctc tcc cac ctg	2389
His Leu Cys Met Arg Gln Glu Ala Tyr Leu Glu Ala Leu Ser His Leu	
720 725 730	
cag tcc cca ctc gac ccc agc acc ctg ctg gct gaa gtc tgc gtg gag	2437
Gln Ser Pro Leu Asp Pro Ser Thr Leu Leu Ala Glu Val Cys Val Glu	
735 740 745	
cag tgc acc ttc atg gac tcc aag atg aag ccc ctg tgg atc atg tac	2485
Gln Cys Thr Phe Met Asp Ser Lys Met Lys Pro Leu Trp Ile Met Tyr	
750 755 760	
agc aac gag gag gca ggc agc ggc ggc agc gtg ggc atc atc ttt aag	2533
Ser Asn Glu Glu Ala Gly Ser Gly Gly Ser Val Gly Ile Ile Phe Lys	
765 770 775	
aac ggg gat gac ctc cgg cag gac atg ctg acc ctg cag atg atc cag	2581
Asn Gly Asp Asp Leu Arg Gln Asp Met Leu Thr Leu Gln Met Ile Gln	
780 785 790 795	
ctc atg gac gtc ctg tgg aag cag gag ggg ctg gac ctg agg atg acc	2629
Leu Met Asp Val Leu Trp Lys Gln Glu Gly Leu Asp Leu Arg Met Thr	

6

His Asn Val Ser Lys Asp Asn Arg Gln
1040

cccaagagga ggcggctgcg ggtcgtgggg accaagcaca ttggtcctaa aggggctgaa 3411
gagcctgaac tgcacctaac gggaaagaac cgacatggct gccttttgtt tacactgggtt 3471
atttatttat gacttgaaat agtttaagga gctaaacagc cataaacgga aacgcctcct 3531
tcatgcagcg gcggtgctgg gcccccgag gctgcacctg gctctcggct gaggattgtc 3591
accccaagtc ttccagctgg tggatctggg ccagcaaaag actgttctcc tcccagaggga 3651
accttcttcc caggcctccc gccagactgc ctgggtcctg gcgcctggcg gtcacctggt 3711
gectactgtc cgacaggatg ccttgatcct cgtgcgaccc accctgtgta tcttccttag 3771
actgagttct ggcagctccc cgaggcagcc ggggtacct ctagattcag ggatgcttgc 3831
tctccacttt tcaagtgggt cttgggtacg agaattc 3868

<210> 2
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 2
tcccgaatg ccaacct 17

<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 3
tgtggaagag cggtcatac t 21

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 4
agctgctgtg gcaccgcgc 19

<210> 5

7

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 5
gaaggtgaag gtcggagtc

19

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 6
gaagatggtg atgggatttc

20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 7
caagcttccc gttctcagcc

20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 8
cggccgctcg tgccgaattc

20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 9
gcgcagctgg cagggtctggg

20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 10
aatgagtgtc atcccgccct 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 11
ggcagattaa agatgcttta 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 12
tggaatagtc caagaaagac 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 13
gatgacagtt gtcctctctg 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 14
ctgcgttggtt acttcccaga 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 15
tcctgcgttg ttacttccca 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 16
gcatacctgcg ttgttacttc 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 17
ggggcatcct gcgttggtac 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
cagggggcat cctgcgttgt 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19

10

ccccaggggg catcctgcgt

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20

ccaccccagg gggcatcctg

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21

agtccacccc agggggcatc

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

ggcagtcac cccagggggc

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

agaccctgt gggcagcagg

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24
cgttgctcgt cctccagctc 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
ggacgggcag gaagggctgc 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
gcggcacgtc cttggtggac 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
cggtgctcc agggaccaca 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
ccccggtctt aagctggtcc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

```
<400> 29
ggaagctgaa gtctagcagc                20
```

```
<400> 30
aatccccag aaagtggcca 20
```

<400> 31
actgcctggt gtctttggac 20

<400> 32
actactgcct gttgtctttg 20

```
<400> 33
gccactactg cctgttgtct                                20
```

```
<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Antisense Oligonucleotide

<400> 34
ggagccacta ctgcctgttg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
ggaggagcca ctactgcctg 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
ctgggaggag ccactactgc 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
gggctgggag gagccactac 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
ccagggtgg gaggagccac 20

<210> 39
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39

cctcctcttg ggcccagggc

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40

accaatgtgc ttggtcccca

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41

gtcggttctt tcccgtagg

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42

atgaaggagg cgtttccgtt

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

cagccgagag ccaggtgcag

20

<210> 44

<211> 20

20

20

20

20

-1-

ANTISENSE MODULATION OF PI3 KINASE P110 DELTA EXPRESSION**FIELD OF THE INVENTION**

The present invention provides compositions and
5 methods for modulating the expression of PI3 kinase p110
delta. In particular, this invention relates to antisense
compounds, particularly oligonucleotides, specifically
hybridizable with nucleic acids encoding human PI3 kinase
p110 delta. Such oligonucleotides have been shown to
10 modulate the expression of PI3 kinase p110 delta.

BACKGROUND OF THE INVENTION

Many growth factors and hormones such as nerve growth
factor (NGF), platelet derived growth factor (PDGF),
epidermal growth factor (EGF) and insulin mediate their
15 signals through interactions with cell surface tyrosine
kinase receptors. The transduction of extracellular
signals across the membrane, initiated by ligand binding,
leads to the propagation of multiple signaling events which
ultimately control target biochemical pathways within the
20 cell.

The phosphatidylinositol 3-kinases (PI3 kinases or
PI3Ks) represent a ubiquitous family of heterodimeric lipid
kinases that are found in association with the cytoplasmic
domain of hormone and growth factor receptors and oncogene
25 products. PI3Ks act as downstream effectors of these
receptors, are recruited upon receptor stimulation and
mediate the activation of second messenger signaling
pathways through the production of phosphorylated
derivatives of inositol. PI3Ks phosphorylate
30 phosphatidylinositol (PtdIns) at the 3'-hydroxyl of the
inositol ring and substrates include PtdIns,
PtIns(4)phosphate, PtdIns(4,5)bisphosphate and
PtdIns(3,4,5) triphosphate with the major product being
PtdIns(3,4,5)triphosphate (Fry, *Biochim. Biophys. Acta.*,
35 1994, 1226, 237-268).

-2-

PI3Ks have been implicated in many cellular activities including growth factor mediated cell transformation, mitogenesis, protein trafficking, cell survival and proliferation, DNA synthesis, apoptosis, neurite outgrowth and insulin-stimulated glucose transport reviewed in (Fry, *Biochim. Biophys. Acta.*, 1994, 1226, 237-268).

The PI3 kinase enzyme heterodimers consist of a 110 kD (p110) catalytic subunit associated with an 85 kD (p85) regulatory subunit and it is through the SH2 domains of the p85 subunit that the enzyme associates with the membrane-bound receptors. Multiple isoforms of the p110 catalytic subunit have been reported and they have been divided into three classes, IA and IB, II, and III. Class IA includes the alpha, beta and delta isoforms all of which bind to p85 and associate with receptor tyrosine kinases (Hu et al., *Mol. Cell. Biol.*, 1993, 13, 7677-7688; Stirdivant et al., *Bioorg. Med. Chem.*, 1997, 5, 65-74; Vanhaesebroeck et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 4330-4335). While the alpha and beta isoforms are ubiquitously expressed, the delta isoform is found only in white blood cells (Vanhaesebroeck et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 4330-4335). Class IB includes the gamma isoform of p110 which exhibits no p85 binding, is regulated by the α and $\beta\gamma$ subunits of G-proteins, and contains unique C2 domains (Stoyanov et al., *Science*, 1995, 269, 690-693). Classes II and III contain the cpk and Vps34p isoforms, respectively (Molz et al., *J. Biol. Chem.*, 1996, 271, 13892-13899; Schu et al., *Science*, 1993, 260, 88-91).

PI3 kinase p110 delta is the most recent catalytic isoform to be isolated (Vanhaesebroeck et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 4330-4335). Unlike other members of the class IA isoforms, the delta isoform has distinct biochemical and structural properties. For example, it does not phosphorylate the p85 subunit but

-3-

instead contains an intrinsic autophosphorylation capacity. In addition the delta isoform has a restricted pattern of expression, that being to white blood cells. A potential role for PI3 kinase p110 delta in cytokine signaling is suggested by its localization to subpopulations of these cells involved in migration. Investigations of the coupling of the delta isoform to receptor complexes in myeloid and lymphoid cell lines revealed that PI3 kinase p110 delta may play a role in leukocyte transendothelial migration (Vanhaesebroeck et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 4330-4335).

Other studies implicate the PI3 kinase p110 delta isoform in nitric oxide signaling. It has been demonstrated that nitrosative and oxidative stressors can trigger ras- and PI3 kinase-regulated events in the cell. Studies of redox signaling in human T cells showed that only the beta and delta isoforms of PI3 kinase p110 were recruited to the membrane upon free radical generation from nitric oxide donors (Deora et al., *J. Biol. Chem.*, 1998, 273, 29923-29928). These findings suggest a role for PI3 kinase beta in inflammatory conditions such as rheumatoid arthritis and asthma.

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of PI3 kinase p110 delta.

To date, strategies aimed at inhibiting PI3 kinase p110 delta function have involved the use of antibodies and chemical inhibitors.

Several chemically distinct inhibitors for PI3 kinases are reported in the literature. These include wortmannin, a fungal metabolite (Ui et al., *Trends Biochem. Sci.*, 1995, 20, 303-307); demethoxyviridin, an antifungal agent (Woscholski et al., *FEBS Lett.*, 1994, 342, 109-114) and quercetin and LY294002, two related chromones (Vlahos et al., *J. Biol. Chem.*, 1994, 269, 5241-5248). However, these

-4-

strategies are untested as therapeutic protocols as well as being non-specific to the PI3 kinase p110 delta isoform. Antisense regulators of p110 delta are generally disclosed in WO 98/23760 (Chantry et al.). Antisense oligonucleotides
5 that selectively bind to a nucleic acid molecule encoding a PI3K delta protein , to decrease transcription and/or translation of PI3K delta genes are also generally disclosed in WO 97/46688 (Vanhasenbroeck et al.) However, these strategies are also untested as therapeutic
10 protocols. Consequently, there remains a long felt need for additional agents capable of effectively inhibiting PI3 kinase p110 delta function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and
15 may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of PI3 kinase p110 delta expression.

SUMMARY OF THE INVENTION

The present invention is directed to antisense
20 compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding PI3 kinase p110 delta, and which modulate the expression of PI3 kinase p110 delta. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided.
25 Further provided are methods of modulating the expression of PI3 kinase p110 delta in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal,
30 particularly a human, suspected of having or being prone to a disease or condition associated with expression of PI3 kinase p110 delta by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

-5-

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding PI3 kinase p110 delta, ultimately modulating the amount of PI3 kinase p110 delta produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding PI3 kinase p110 delta. As used herein, the terms "target nucleic acid" and "nucleic acid encoding PI3 kinase p110 delta" encompass DNA encoding PI3 kinase p110 delta, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of PI3 kinase p110 delta. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention,

-6-

is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding PI3 kinase p110 delta. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate

-7-

translation of an mRNA molecule transcribed from a gene encoding PI3 kinase p110 delta, regardless of the sequence(s) of such codons.

It is also known in the art that a translation
5 termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and
10 "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination
15 codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the
20 translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the
25 translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3'
30 direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA
35 via a 5'-5' triphosphate linkage. The 5' cap region of an

-8-

mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly
5 translated, many contain one or more regions, known as
"introns," which are excised from a transcript before it is
translated. The remaining (and therefore translated)
regions are known as "exons" and are spliced together to
form a continuous mRNA sequence. mRNA splice sites, i.e.,
10 intron-exon junctions, may also be preferred target
regions, and are particularly useful in situations where
aberrant splicing is implicated in disease, or where an
overproduction of a particular mRNA splice product is
implicated in disease. Aberrant fusion junctions due to
15 rearrangements or deletions are also preferred targets. It
has also been found that introns can also be effective, and
therefore preferred, target regions for antisense compounds
targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified,
20 oligonucleotides are chosen which are sufficiently
complementary to the target, i.e., hybridize sufficiently
well and with sufficient specificity, to give the desired
effect.

In the context of this invention, "hybridization"
25 means hydrogen bonding, which may be Watson-Crick,
Hoogsteen or reversed Hoogsteen hydrogen bonding, between
complementary nucleoside or nucleotide bases. For example,
adenine and thymine are complementary nucleobases which
pair through the formation of hydrogen bonds.
30 "Complementary," as used herein, refers to the capacity for
precise pairing between two nucleotides. For example, if a
nucleotide at a certain position of an oligonucleotide is
capable of hydrogen bonding with a nucleotide at the same
position of a DNA or RNA molecule, then the oligonucleotide
35 and the DNA or RNA are considered to be complementary to

-9-

each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as

-10-

therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term

"oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines.

-11-

Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having

-12-

normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;

-13-

5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of
which are commonly owned with this application, and each of
5 which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the
sugar and the internucleoside linkage, i.e., the backbone,
of the nucleotide units are replaced with novel groups.
The base units are maintained for hybridization with an
10 appropriate nucleic acid target compound. One such
oligomeric compound, an oligonucleotide mimetic that has
been shown to have excellent hybridization properties, is
referred to as a peptide nucleic acid (PNA). In PNA
compounds, the sugar-backbone of an oligonucleotide is
15 replaced with an amide containing backbone, in particular
an aminoethylglycine backbone. The nucleobases are
retained and are bound directly or indirectly to aza
nitrogen atoms of the amide portion of the backbone.
Representative United States patents that teach the
20 preparation of PNA compounds include, but are not limited
to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of
which is herein incorporated by reference. Further teaching
of PNA compounds can be found in Nielsen et al., *Science*,
1991, 254, 1497-1500.

25 Most preferred embodiments of the invention are
oligonucleotides with phosphorothioate backbones and
oligonucleosides with heteroatom backbones, and in
particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a
methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$,
30 $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the
native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$
] of the above referenced U.S. patent 5,489,677, and the
amide backbones of the above referenced U.S. patent
5,602,240. Also preferred are oligonucleotides having
35 morpholino backbone structures of the above-referenced U.S.

-14-

patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-
5 , S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂,
10 and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃,
15 ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the
20 pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy
25 group. A further preferred modification includes 2'-dimethylaminoethoxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-
30 O-CH₂-N(CH₂)₂, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3'
35 position of the sugar on the 3' terminal nucleotide or in

-15-

2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 10 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often 15 referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other 20 synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl 25 and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 30 3,687,808, those disclosed in *The Concise Encyclopedia Of*

-16-

Polymer Science And Engineering, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S.,

5 Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines,

10 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds.,

15 *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the

20 preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;

25 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the

30 instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which

-17-

enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxcholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830;

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds.

"Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target

-19-

region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

5 Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to
10 in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.:
5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878;
5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355;
15 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through
20 the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well
25 known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector
30 constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor
35 targeted molecules, oral, rectal, topical or other

-20-

formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not
5 limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295;
10 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such
15 esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically
20 acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an
25 active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to
30 the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of
35 the compounds of the invention: i.e., salts that retain the

-21-

desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid,

-22-

succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid,

-23-

tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed
5 from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an
10 animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of PI3 kinase p110 delta is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized
15 in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay
20 infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding PI3 kinase p110 delta, enabling sandwich and other assays to easily be constructed
25 to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding PI3 kinase p110 delta can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the
30 oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of PI3 kinase p110 delta in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense
35 compounds of the invention. The pharmaceutical

-24-

compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and

-25-

liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

5 The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association
10 the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the
15 product.

 The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the
20 present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The
25 suspension may also contain stabilizers.

 In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams,
30 jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may

-26-

be applied to the formulation of the compositions of the present invention.

Emulsions

5 The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*,
10 Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman,
15 Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases
20 intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a
25 water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to
30 the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed.

-27-

Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex
5 formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water
10 stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into
15 the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing
20 emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in
25 *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of
30 emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc.,
35 New York, N.Y., 1988, volume 1, p. 199). Surfactants are

-28-

typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool
5 in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*,
10 Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic
15 properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous
20 preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as
25 carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants,
30 hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel
35 Dekker, Inc., New York, N.Y., volume 1, p. 199).

-29-

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth),
5 cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming
10 strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides
15 that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic
20 acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing
25 agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for
30 their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of
35 ease of formulation, efficacy from an absorption and

-30-

bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

10 In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar

-31-

heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300,

-32-

PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, 5 di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the 10 standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 15 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in 20 membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often 25 microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active 30 components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the

-33-

gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

5 Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and
10 nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et
15 *al.*, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

20 There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and
25 the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

 Liposomes are unilamellar or multilamellar vesicles
30 which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as
35 efficiently with the cell wall, are taken up by macrophages

-34-

in vivo.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a
5 suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and
10 biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988,
15 Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of
20 active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the
25 liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical
30 administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to
35 administer a wide variety of drugs, both hydrophilic and

-35-

hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed

-36-

from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming

-37-

lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood

-38-

half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klivanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic

-40-

products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol
5 esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The
10 polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include
15 carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important
20 members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include
25 quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is
30 classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in

Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

5 In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually
10 only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs
15 across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-
20 surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

25 Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and
30 another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl
35 ether) (Lee et al., *Critical Reviews in Therapeutic Drug*

Carrier Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprinate, tricaprinate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprinate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

20

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium

30

-43-

glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate),
5 ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical*
10 *Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

15

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that
20 absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal
25 ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of
30 collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi,

Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-
5 chelating non-surfactant penetration enhancing compounds
can be defined as compounds that demonstrate insignificant
activity as chelating agents or as surfactants but that
nonetheless enhance absorption of oligonucleotides through
the alimentary mucosa (Muranishi, *Critical Reviews in*
10 *Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This
class of penetration enhancers include, for example,
unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-
alkanone derivatives (Lee et al., *Critical Reviews in*
Therapeutic Drug Carrier Systems, 1991, page 92); and non-
15 steroidal anti-inflammatory agents such as diclofenac
sodium, indomethacin and phenylbutazone (Yamashita et al.,
J. Pharm. Pharmacol., 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the
cellular level may also be added to the pharmaceutical and
20 other compositions of the present invention. For example,
cationic lipids, such as lipofectin (Junichi et al, U.S.
Patent No. 5,705,188), cationic glycerol derivatives, and
polycationic molecules, such as polylysine (Lollo et al.,
PCT Application WO 97/30731), are also known to enhance the
25 cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the
penetration of the administered nucleic acids, including
glycols such as ethylene glycol and propylene glycol,
pyrrols such as 2-pyrrol, azones, and terpenes such as
30 limonene and menthone.

Carriers

Certain compositions of the present invention also
incorporate carrier compounds in the formulation. As used

-45-

herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose,

-46-

etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

-47-

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine,

-48-

cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual* 5 *of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, 10 acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents 15 are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic 20 acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their 25 subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution 30 of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on 35 the relative potency of individual oligonucleotides, and

-49-

can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, 5 monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be 10 desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

15 While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

20 **EXAMPLES**

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl 25 phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides 30 synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine 35 (5-Me-C) nucleotides were synthesized according to

-50-

published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

5 **2'-Fluoro amidites**

2'-Fluorodeoxyadenosine amidites

 2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

 The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups.

-51-

Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

10 2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

20 2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum

-52-

was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70%

-53-

product. The solvent was evaporated and triturated with CH_3CN (200 mL). The residue was dissolved in CHCl_3 (1.5 L) and extracted with 2x500 mL of saturated NaHCO_3 and 2x500 mL of saturated NaCl . The organic phase was dried over Na_2SO_4 ,
5 filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc /hexane/acetone (5:5:1) containing 0.5% Et_3NH . The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional
10 was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine
15 (106 g, 0.167 M), DMF /pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the
20 addition of MeOH . Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C . The residue was dissolved in CHCl_3 (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl . The water
25 layers were back extracted with 200 mL of CHCl_3 . The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc /hexane(4:1). Pure product fractions were
30 evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-
35 acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-

-54-

methylluridine (96 g, 0.144 M) in CH_3CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH_3CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl_3 was added dropwise, over a 30 minute period, to the stirred solution maintained at $0-10^\circ\text{C}$, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO_3 and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH_4OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH_3 gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyl-

-55-

cytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was
5 evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl_3 (700 mL) and extracted with saturated NaHCO_3 (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO_4 and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica
10 column using EtOAc/hexane (1:1) containing 0.5% Et_3NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

15 N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting
20 mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH_2Cl_2 (300 mL), and the extracts were
25 combined, dried over MgSO_4 and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

30 **2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside

-56-

amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until

-57-

the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL,

-58-

44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred
5 for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-
10 butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-
15 5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and
20 dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under
25 vacuum; residue chromatographed to get 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

30 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this

-59-

solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

2'-O-(dimethylaminoxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

-60-

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine

2'-O-(dimethylaminooxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P_2O_5 under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH_2Cl_2 (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P_2O_5 under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous $NaHCO_3$ (40mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

-61-

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs.

- 5 Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

- 10 The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor
15 amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501 A1 940203.) Standard protection procedures
20 should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-
25 5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-
30 dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also

-62-

known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

5 **2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

25 **5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel

-63-

chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

15 Example 2

Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

-64-

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,

-65-

5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

10 PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 15 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

20 Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked 25 nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are 30 also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligo-

-66-

nucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphor-
 5 amidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The
 10 fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect
 15 all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25
 20 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate

25 Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.
 30

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phos-

-67-

phorothioate]--[2'-O-(methoxyethyl) phosphodiester]
chimeric oligonucleotides are prepared as per the above
procedure for the 2'-O-methyl chimeric oligonucleotide with
the substitution of 2'-O-(methoxyethyl) amidites for the
5 2'-O-methyl amidites, oxidization with iodine to generate
the phosphodiester internucleotide linkages within the
wing portions of the chimeric structures and sulfurization
utilizing 3,4-dithiolane-2-one 1,1 dioxane (Beaucage
Reagent) to generate the phosphorothioate internucleotide
10 linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleo-
sides and mixed chimeric oligonucleotides/oligonucleosides
are synthesized according to United States patent
5,623,065, herein incorporated by reference.

15 **Example 6**

Oligonucleotide Isolation

After cleavage from the controlled pore glass column
(Applied Biosystems) and deblocking in concentrated
ammonium hydroxide at 55°C for 18 hours, the
20 oligonucleotides or oligonucleosides are purified by
precipitation twice out of 0.5 M NaCl with 2.5 volumes
ethanol. Synthesized oligonucleotides were analyzed by
polyacrylamide gel electrophoresis on denaturing gels and
judged to be at least 85% full length material. The
25 relative amounts of phosphorothioate and phosphodiester
linkages obtained in synthesis were periodically checked by
³¹P nuclear magnetic resonance spectroscopy, and for some
studies oligonucleotides were purified by HPLC, as
described by Chiang et al., *J. Biol. Chem.* **1991**, 266,
30 18162-18171. Results obtained with HPLC-purified material
were similar to those obtained with non-HPLC purified
material.

-68-

Example 7**Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8**Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test

The human lung carcinoma cell line A549 was obtained
35 from the American Type Culture Collection (ATCC) (Manassas,

-70-

VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

10 NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium was

-71-

replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

Example 10

Analysis of oligonucleotide inhibition of PI3 kinase p110

5 delta expression

Antisense modulation of PI3 kinase p110 delta expression can be assayed in a variety of ways known in the art. For example, PI3 kinase p110 delta mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive
10 polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular*
15 *Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-
20 time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are also known in the
25 art.

PI3 kinase p110 delta protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell
30 sorting (FACS). Antibodies directed to PI3 kinase p110 delta can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for

-72-

preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc.,

-73-

Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack

-74-

containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μ L water.

5 The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are
10 carried out.

Example 13

Real-time Quantitative PCR Analysis of PI3 kinase p110 delta mRNA Levels

Quantitation of PI3 kinase p110 delta mRNA levels was
15 determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput
20 quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by
25 including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City,
30 CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by
35 the proximity of the 3' quencher dye. During

-75-

amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM $MgCl_2$, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). PI3 kinase p110 delta probes and primers were designed to hybridize to the human PI3 kinase p110 delta sequence, using published sequence information (GenBank accession number Y10055, incorporated herein as SEQ ID NO:1).

For PI3 kinase p110 delta the PCR primers were:
forward primer: TCCCGCAATGCCAACCT (SEQ ID NO: 2)

-76-

reverse primer: TGTGGAAGAGCGGCTCATACT (SEQ ID NO: 3) and the PCR probe was: FAM-AGCTGCTGTGGCACCGCGC-TAMRA (SEQ ID NO: 4) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

For GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 5)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 6) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 7) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Example 14

Northern blot analysis of PI3 kinase p110 delta mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA).

Membranes were probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions with a PI3 kinase p110 delta specific probe prepared by PCR using the forward primer TCCCGCAATGCCAACCT (SEQ ID NO: 2) and the reverse primer TGTGGAAGAGCGGCTCATACT (SEQ ID NO: 3). To normalize

-77-

for variations in loading and transfer efficiency membranes were stripped and probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using
5 a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

10 Antisense inhibition of PI3 kinase p110 delta expression-phosphorothioate oligodeoxynucleotides

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human PI3 kinase p110 delta RNA, using published sequences (GenBank accession number Y10055, incorporated
15 herein as SEQ ID NO: 1). The oligonucleotides are shown in Table 1. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. Y10055), to which the oligonucleotide binds. All compounds in Table 1 are oligodeoxynucleotides with
20 phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on PI3 kinase p110 delta mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no
25 data".

Table 1

Inhibition of PI3 kinase p110 delta mRNA levels by phosphorothioate oligodeoxynucleotides

30	ISIS#	REGION	TARGET SITE	SEQUENCE	%	SEQ ID NO.
					Inhibition	
	32120	5' UTR	1	cggccgctcgtgccgaattc	4	8
	32121	5' UTR	33	gcgcagctggcagggctggg	14	9
	32122	5' UTR	75	aatgagtgtcatcccgccct	60	10
	32123	5' UTR	100	ggcagattaaagatgcttta	10	11
35	32124	5' UTR	140	tggaatagtccaagaaagac	0	12
	32125	5' UTR	158	gatgacagttgtcctctctg	16	13

WO 01/05958

PCT/US00/00525

-78-

	32126	5' UTR	176	ctgcgttggttacttcccaga	0	14
	32127	Start Codon	178	tcctgcgttggttacttccca	24	15
	32128	Start Codon	181	gcatacctgcgttggttacttc	11	16
	32129	Start Codon	184	ggggcatcctgcgttggttac	0	17
5	32130	Start Codon	187	cagggggcatcctgcgttggt	15	18
	32131	Start Codon	190	ccccagggggcatcctgcgt	19	19
	32132	Start Codon	193	ccaccccagggggcatcctg	0	20
	32133	Start Codon	196	agtccaccccagggggcatc	0	21
	32134	Start Codon	199	ggcagtcaccccaggggggc	24	22
10	32135	Coding	268	agacccctgtgggcagcagg	22	23
	32136	Coding	437	cggtgctcgtcctccagctc	53	24
	32137	Coding	472	ggacgggcaggaagggtgc	0	25
	32138	Coding	817	gcggcacgtccttggtggac	7	26
	32139	Coding	1143	cggctgctccagggaaccaca	37	27
15	32140	Coding	1483	ccccgggtcttaagctggtcc	69	28
	32141	Coding	1939	ggaagctgaagtctagcagc	16	29
	32142	Coding	2932	aattccccagaaagtggcca	26	30
	32143	Coding	3310	actgcctgttggtctttggac	26	31
	32144	Stop Codon	3313	actactgcctgttggtctttg	0	32
20	32145	Stop Codon	3316	gccactactgcctgttggtct	41	33
	32146	Stop Codon	3319	ggagccactactgcctgttg	14	34
	32147	Stop Codon	3322	ggaggagccactactgcctg	2	35
	32148	Stop Codon	3325	ctgggaggagccactactgc	1	36
	32149	Stop Codon	3328	gggctgggaggagccactac	0	37
25	32150	Stop Codon	3331	ccagggctgggaggagccac	9	38
	32151	3' UTR	3344	cctcctcttgggcccagggc	0	39
	32152	3' UTR	3377	accaatgtgcttggtcccca	0	40
	32153	3' UTR	3426	gtcggttctttcccgtagg	48	41
	32154	3' UTR	3516	atgaaggaggcggttccggt	19	42
30	32155	3' UTR	3563	cagccgagagccagggtgcag	0	43
	32156	3' UTR	3630	cctcgggaggagaaacagtct	0	44

-79-

32157	3' UTR	3699	agtaggcaccagggtgaccgc	23	45
32158	3' UTR	3769	agctgccagaactcagtcta	47	46
32159	3' UTR	3832	accacttgaaaagtggaga	1	47

5 As shown in Table 1, SEQ ID NOS 10, 15, 22, 23, 24, 27, 28, 30, 31, 33, 41, 45 and 46 demonstrated at least 20% inhibition of PI3 kinase p110 delta expression in this assay and are therefore preferred.

Example 16:

10 **Antisense inhibition of PI3 kinase p110 delta expression-phosphorothioate 2'-MOE gapmer oligonucleotides**

15 In accordance with the present invention, a second series of oligonucleotides targeted to human PI3 kinase p110 delta were synthesized. The oligonucleotide sequences are shown in Table 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. Y10055), to which the oligonucleotide binds.

20 All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines.

25 Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments. If present, "N.D." indicates "no data".

30

-80-

Table 2

Inhibition of PI3 kinase p110 delta mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

5	ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
	32160	5' UTR	1	cggccgctcgtgccgaattc	0	8
	32161	5' UTR	33	gcgcagctggcagggctggg	0	9
	32162	5' UTR	75	aatgagtgtcatcccgccct	86	10
10	32163	5' UTR	100	ggcagattaaagatgcttta	52	11
	32164	5' UTR	140	tggaaatagccaagaaagac	0	12
	32165	5' UTR	158	gatgacagttgtcctctctg	54	13
	32166	5' UTR	176	ctgcgttggttacttcccaga	59	14
	32167	Start Codon	178	tcctgcgttggttacttccca	78	15
15	32168	Start Codon	181	gcatacctgcgttggttacttc	65	16
	32169	Start Codon	184	ggggcatcctgcgttggttac	0	17
	32170	Start Codon	187	cagggggcatcctgcgttgt	0	18
	32171	Start Codon	190	ccccagggggcatcctgcgt	4	19
	32172	Start Codon	193	ccaccccagggggcatcctg	63	20
20	32173	Start Codon	196	agtccaccccagggggcatc	55	21
	32174	Start Codon	199	ggcagtcaccccagggggc	44	22
	32175	Coding	268	agaccctgtgggcagcagg	54	23
	32176	Coding	437	cgttgctcgtcctccagctc	73	24
	32177	Coding	472	ggacgggcaggaagggtgc	13	25
25	32178	Coding	817	gcggcacgtccttggtggac	46	26
	32179	Coding	1143	cggctgctccaggaccaca	62	27
	32180	Coding	1483	ccccggtcttaagctggtcc	58	28
	32181	Coding	1939	ggaagctgaagtctagcagc	44	29
	32182	Coding	2932	aattccccagaaagtggcca	50	30
30	32183	Coding	3310	actgcctggtgtctttggac	56	31
	32184	Stop Codon	3313	actactgcctggtgtctttg	56	32
	32185	Stop Codon	3316	gccactactgcctggtgtct	70	33
	32186	Stop Codon	3319	ggagccactactgcctggtg	69	34

-81-

	32187	Stop Codon	3322	ggaggagccactactgcctg	45	35
	32188	Stop Codon	3325	ctgggaggagccactactgc	40	36
	32189	Stop Codon	3328	gggctgggaggagccactac	0	37
	32190	Stop Codon	3331	ccagggctgggaggagccac	31	38
5	32191	3' UTR	3344	cctcctcttgggcccagggc	29	39
	32192	3' UTR	3377	accaatgtgcttggtcccca	63	40
	32193	3' UTR	3426	gtcggttctttcccgttagg	65	41
	32194	3' UTR	3516	atgaaggaggcgtttccggt	68	42
	32195	3' UTR	3563	cagccgagagccagggtgcag	41	43
10	32196	3' UTR	3630	cctcgggaggagaacagtct	55	44
	32197	3' UTR	3699	agtaggcaccagggtgaccgc	33	45
	32198	3' UTR	3769	agctgccagaactcagtcta	52	46
	32199	3' UTR	3832	accacttgaaaagtggaga	20	47

15 As shown in Table 2, SEQ ID NOS 10, 11, 13, 14, 15, 16, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47 demonstrated at least 20% inhibition of PI3 kinase p110 delta expression in this experiment and are therefore
20 preferred.

Example 17

Western blot analysis of PI3 kinase p110 delta protein levels

Western blot analysis (immunoblot analysis) is carried
25 out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western
30 blotting. Appropriate primary antibody directed to PI3 kinase p110 delta is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

-82-

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human PI3 kinase p110 delta, wherein said antisense compound specifically hybridizes with and inhibits the expression of
5 human PI3 kinase p110 delta.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID
10 NO: 10, 15, 22, 23, 24, 27, 28, 30, 31, 33, 41, 45, 46, 11, 13, 14, 16, 20, 21, 26, 29, 32, 34, 35, 36, 38, 39, 40, 42, 43, 44 or 47.
4. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID
15 NO: 10, 15, 22, 23, 24, 27, 28, 30, 31, 33, 41, 45 or 46.
5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
6. The antisense compound of claim 5 wherein the
20 modified internucleoside linkage is a phosphorothioate linkage.
7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 25 8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 30 10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.
11. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
12. A composition comprising the antisense compound

-83-

of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the
5 antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of PI3 kinase p110 delta in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of PI3 kinase p110
10 delta is inhibited.

16. A method of treating a human having a disease or condition associated with PI3 kinase p110 delta comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound
15 of claim 1 so that expression of PI3 kinase p110 delta is inhibited.

17. The method of claim 16 wherein the disease or condition is an inflammatory disorder.

18. The method of claim 17 wherein the inflammatory
20 disorder is asthma.

19. The method of claim 17 wherein the inflammatory disorder is rheumatoid arthritis.

1007-13-06-1002
757-837

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05958 A1

- (51) International Patent Classification⁷: C12N 15/00, 15/11, C12Q 1/68, A61K 48/00
- (74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: PCT/US00/00525
- (22) International Filing Date: 6 January 2000 (06.01.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/357,070 19 July 1999 (19.07.1999) US
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MONIA, Brett, P. [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). COWSERT, Lex, M. [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/05958 A1

(54) Title: ANTISENSE MODULATION OF P13 KINASE P110 DELTA EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of P13 kinase p110 delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding P13 kinase p110 delta. Methods of using these compounds for modulation of P13 kinase p110 delta expression and for treatment of diseases associated with expression of P13 kinase p110 delta are provided.

WO 01/05958

PCT/US00/00525

SEQUENCE LISTING

<110> Brett P. Monia
Lex M. Cowser
ISIS PHARMACEUTICALS, INC.

<120> ANTISENSE MODULATION OF PI3 KINASE P110 DELTA EXPRESSION

<130> RTSP-0041

<150> US 09/357,070

<151> 1999-07-19

<160> 47

<210> 1

<211> 3868

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (197)..(3331)

<400> 1

```

gaattcggca cgagcggccg cgagcagagc cgcccagccc tgccagctgc gccggggacga      60
taaggagtca ggccagggcg ggatgacact cattgattct aaagcatctt taatctgccca      120
ggcggagggg gctttgctgg tctttcttgg actattccag agaggacaac tgtcatctgg      180
gaagtaacaa cgcagg atg ccc cct ggg gtg gac tgc ccc atg gaa ttc      229
                Met Pro Pro Gly Val Asp Cys Pro Met Glu Phe
                1                5                10

tgg acc aag gag gag aat cag agc gtt gtg gtt gac ttc ctg ctg ccc      277
Trp Thr Lys Glu Glu Asn Gln Ser Val Val Val Asp Phe Leu Leu Pro
                15                20                25

aca ggg gtc tac ctg aac ttc cct gtg tcc cgc aat gcc aac ctc agc      325
Thr Gly Val Tyr Leu Asn Phe Pro Val Ser Arg Asn Ala Asn Leu Ser
                30                35                40

acc atc aag cag ctg ctg tgg cac cgc gcc cag tat gag ccg ctc ttc      373
Thr Ile Lys Gln Leu Leu Trp His Arg Ala Gln Tyr Glu Pro Leu Phe
                45                50                55

cac atg ctc agt ggc ccc gag gcc tat gtg ttc acc tgc atc aac cag      421
His Met Leu Ser Gly Pro Glu Ala Tyr Val Phe Thr Cys Ile Asn Gln
                60                65                70                75

aca gcg gag cag caa gag ctg gag gac gag caa cgg cgt ctg tgt gac      469
Thr Ala Glu Gln Gln Glu Leu Glu Asp Glu Gln Arg Arg Leu Cys Asp
                80                85                90

gtg cag ccc ttc ctg ccc gtc ctg cgc ctg gtg gcc cgt gag ggc gac      517
Val Gln Pro Phe Leu Pro Val Leu Arg Leu Val Ala Arg Glu Gly Asp
                95                100                105

```

WO 01/05958

PCT/US00/00525

cgc	gtg	aag	aag	ctc	atc	aac	tca	cag	atc	agc	ctc	ctc	atc	ggc	aaa	565
Arg	Val	Lys	Lys	Leu	Ile	Asn	Ser	Gln	Ile	Ser	Leu	Leu	Ile	Gly	Lys	
		110					115					120				
ggc	ctc	cac	gag	ttt	gac	tcc	ttg	tgc	gac	cca	gaa	gtg	aac	gac	ttt	613
Gly	Leu	His	Glu	Phe	Asp	Ser	Leu	Cys	Asp	Pro	Glu	Val	Asn	Asp	Phe	
	125					130					135					
cgc	gcc	aag	atg	tgc	caa	ttc	tgc	gag	gag	gcg	gcc	gcc	cgc	cgg	cag	661
Arg	Ala	Lys	Met	Cys	Gln	Phe	Cys	Glu	Glu	Ala	Ala	Ala	Arg	Arg	Gln	
140					145					150					155	
cag	ctg	ggc	tgg	gag	gcc	tgg	ctg	cag	tac	agt	ttc	ccc	ctg	cag	ctg	709
Gln	Leu	Gly	Trp	Glu	Ala	Trp	Leu	Gln	Tyr	Ser	Phe	Pro	Leu	Gln	Leu	
			160						165				170			
gag	ccc	tgc	gct	caa	acc	tgg	ggg	cct	ggt	acc	ctg	cgg	ctc	ccg	aac	757
Glu	Pro	Ser	Ala	Gln	Thr	Trp	Gly	Pro	Gly	Thr	Leu	Arg	Leu	Pro	Asn	
			175					180					185			
cgg	gcc	ctt	ctg	gtc	aac	gtt	aag	ttt	gag	ggc	agc	gag	gag	agc	ttc	805
Arg	Ala	Leu	Leu	Val	Asn	Val	Lys	Phe	Glu	Gly	Ser	Glu	Glu	Ser	Phe	
		190					195					200				
acc	ttc	cag	gtg	tcc	acc	aag	gac	gtg	ccg	ctg	gcg	ctg	atg	gcc	tgt	853
Thr	Phe	Gln	Val	Ser	Thr	Lys	Asp	Val	Pro	Leu	Ala	Leu	Met	Ala	Cys	
	205					210					215					
gcc	ctg	cgg	aag	aag	gcc	aca	gtg	ttc	cgg	cag	ccg	ctg	gtg	gag	cag	901
Ala	Leu	Arg	Lys	Lys	Ala	Thr	Val	Phe	Arg	Gln	Pro	Leu	Val	Glu	Gln	
220					225					230					235	
ccg	gaa	gac	tac	acg	ctg	cag	gtg	aac	ggc	agg	cat	gag	tac	ctg	tat	949
Pro	Glu	Asp	Tyr	Thr	Leu	Gln	Val	Asn	Gly	Arg	His	Glu	Tyr	Leu	Tyr	
			240						245					250		
ggc	agc	tac	ccg	ctc	tgc	cag	ttc	cag	tac	atc	tgc	agc	tgc	ctg	cac	997
Gly	Ser	Tyr	Pro	Leu	Cys	Gln	Phe	Gln	Tyr	Ile	Cys	Ser	Cys	Leu	His	
			255					260					265			
agt	ggg	ttg	acc	cct	cac	ctg	acc	atg	gtc	cat	tcc	tcc	tcc	atc	ctc	1045
Ser	Gly	Leu	Thr	Pro	His	Leu	Thr	Met	Val	His	Ser	Ser	Ser	Ile	Leu	
		270					275					280				
gcc	atg	cgg	gat	gag	cag	agc	aac	cct	gcc	ccc	cag	gtc	cag	aaa	ccg	1093
Ala	Met	Arg	Asp	Glu	Gln	Ser	Asn	Pro	Ala	Pro	Gln	Val	Gln	Lys	Pro	
	285					290					295					
cgt	gcc	aaa	cca	cct	ccc	att	cct	gcg	aag	aag	cct	tcc	tct	gtg	tcc	1141
Arg	Ala	Lys	Pro	Pro	Pro	Ile	Pro	Ala	Lys	Lys	Pro	Ser	Ser	Val	Ser	
300					305					310					315	
ctg	tgg	tcc	ctg	gag	cag	ccg	ttc	cgc	atc	gag	ctc	atc	cag	ggc	agc	1189
Leu	Trp	Ser	Leu	Glu	Gln	Pro	Phe	Arg	Ile	Glu	Leu	Ile	Gln	Gly	Ser	
			320					325					330			
aaa	gtg	aac	gcc	gac	gag	cgg	atg	aag	ctg	gtg	gtg	cag	gcc	ggg	ctt	1237
Lys	Val	Asn	Ala	Asp	Glu	Arg	Met	Lys	Leu	Val	Val	Gln	Ala	Gly	Leu	
			335					340					345			

WO 01/05958

PCT/US00/00525

ttc cac ggc aac gag atg ctg tgc aag acg gtg tcc agc tcg gag gtg	1285
Phe His Gly Asn Glu Met Leu Cys Lys Thr Val Ser Ser Ser Glu Val	
350 355 360	
agc gtg tgc tcg gag ccc gtg tgg aag cag cgg ctg gag ttc gac atc	1333
Ser Val Cys Ser Glu Pro Val Trp Lys Gln Arg Leu Glu Phe Asp Ile	
365 370 375	
aac atc tgc gac ctg ccc cgc atg gcc cgt ctc tgc ttt gcg ctg tac	1381
Asn Ile Cys Asp Leu Pro Arg Met Ala Arg Leu Cys Phe Ala Leu Tyr	
380 385 390 395	
gcc gtg atc gag aaa gcc aag aag gct cgc tcc acc aag aag aag tcc	1429
Ala Val Ile Glu Lys Ala Lys Lys Ala Arg Ser Thr Lys Lys Lys Ser	
400 405 410	
aag aag gcg gac tgc ccc att gcc tgg gcc aac ctc atg ctg ttt gac	1477
Lys Lys Ala Asp Cys Pro Ile Ala Trp Ala Asn Leu Met Leu Phe Asp	
415 420 425	
tac aag gac cag ctt aag acc ggg gaa cgc tgc ctc tac atg tgg ccc	1525
Tyr Lys Asp Gln Leu Lys Thr Gly Glu Arg Cys Leu Tyr Met Trp Pro	
430 435 440	
tcc gtc cca gat gag aag ggc gag ctg ctg aac ccc acg ggc act gtg	1573
Ser Val Pro Asp Glu Lys Gly Glu Leu Leu Asn Pro Thr Gly Thr Val	
445 450 455	
cgc agt aac ccc aac acg gat agc gcc gct gcc ctg ctc atc tgc ctg	1621
Arg Ser Asn Pro Asn Thr Asp Ser Ala Ala Ala Leu Leu Ile Cys Leu	
460 465 470 475	
ccc gag gtg gcc ccg cac ccc gtg tac tac ccc gcc ctg gag aag atc	1669
Pro Glu Val Ala Pro His Pro Val Tyr Tyr Pro Ala Leu Glu Lys Ile	
480 485 490	
ttg gag ctg ggg cga cac agc gag tgt gtg cat gtc acc gag gag gag	1717
Leu Glu Leu Gly Arg His Ser Glu Cys Val His Val Thr Glu Glu Glu	
495 500 505	
cag ctg cag ctg cgg gaa atc ctg gag cgg cgg ggg tct ggg gag ctg	1765
Gln Leu Gln Leu Arg Glu Ile Leu Glu Arg Arg Gly Ser Gly Glu Leu	
510 515 520	
tat gag cac gag aag gac ctg gtg tgg aag ctg cgg cat gaa gtc cag	1813
Tyr Glu His Glu Lys Asp Leu Val Trp Lys Leu Arg His Glu Val Gln	
525 530 535	
gag cac ttc ccg gag gcg cta gcc cgg ctg ctg ctg gtc acc aag tgg	1861
Glu His Phe Pro Glu Ala Leu Ala Arg Leu Leu Leu Val Thr Lys Trp	
540 545 550 555	
aac aag cat gag gat gtg gcc cag atg ctc tac ctg ctg tgc tcc tgg	1909
Asn Lys His Glu Asp Val Ala Gln Met Leu Tyr Leu Leu Cys Ser Trp	
560 565 570	
ccg gag ctg ccc gtc ctg agc gcc ctg gag ctg cta gac ttc agc ttc	1957
Pro Glu Leu Pro Val Leu Ser Ala Leu Glu Leu Leu Asp Phe Ser Phe	
575 580 585	

WO 01/05958

PCT/US00/00525

ccc gat tgc cac gta ggc tcc ttc gcc atc aag tcg ctg cgg aaa ctg Pro Asp Cys His Val Gly Ser Phe Ala Ile Lys Ser Leu Arg Lys Leu 590 595 600	2005
acg gac gat gag ctg ttc cag tac ctg ctg cag ctg gtg cag gtg ctc Thr Asp Asp Glu Leu Phe Gln Tyr Leu Leu Gln Val Gln Val Leu 605 610 615	2053
aag tac gag tcc tac ctg gac tgc gag ctg acc aaa ttc ctg ctg gac Lys Tyr Glu Ser Tyr Leu Asp Cys Glu Leu Thr Lys Phe Leu Leu Asp 620 625 630 635	2101
cgg gcc ctg gcc aac cgc aag atc ggc cac ttc ctt ttc tgg cac ctc Arg Ala Leu Ala Asn Arg Lys Ile Gly His Phe Leu Phe Trp His Leu 640 645 650	2149
cgc tcc gag atg cac gtg ccg tcg gtg gcc ctg cgc ttc ggc ctc atc Arg Ser Glu Met His Val Pro Ser Val Ala Leu Arg Phe Gly Leu Ile 655 660 665	2197
ctg gag gcc tac tgc agg ggc agg acc cac cac atg aag gtg ctg atg Leu Glu Ala Tyr Cys Arg Gly Arg Thr His His Met Lys Val Leu Met 670 675 680	2245
aag cag ggg gaa gca ctg agc aaa ctg aag gcc ctg aat gac ttc gtc Lys Gln Gly Glu Ala Leu Ser Lys Leu Lys Ala Leu Asn Asp Phe Val 685 690 695	2293
aag ctg agc tct cag aag acc ccc aag ccc cag acc aag gag ctg atg Lys Leu Ser Ser Gln Lys Thr Pro Lys Pro Gln Thr Lys Glu Leu Met 700 705 710 715	2341
cac ttg tgc atg cgg cag gag gcc tac cta gag gcc ctc tcc cac ctg His Leu Cys Met Arg Gln Glu Ala Tyr Leu Glu Ala Leu Ser His Leu 720 725 730	2389
cag tcc cca ctc gac ccc agc acc ctg ctg gct gaa gtc tgc gtg gag Gln Ser Pro Leu Asp Pro Ser Thr Leu Leu Ala Glu Val Cys Val Glu 735 740 745	2437
cag tgc acc ttc atg gac tcc aag atg aag ccc ctg tgg atc atg tac Gln Cys Thr Phe Met Asp Ser Lys Met Lys Pro Leu Trp Ile Met Tyr 750 755 760	2485
agc aac gag gag gca ggc agc ggc ggc agc gtg ggc atc atc ttt aag Ser Asn Glu Glu Ala Gly Ser Gly Gly Ser Val Gly Ile Ile Phe Lys 765 770 775	2533
aac ggg gat gac ctc cgg cag gac atg ctg acc ctg cag atg atc cag Asn Gly Asp Asp Leu Arg Gln Asp Met Leu Thr Leu Gln Met Ile Gln 780 785 790 795	2581
ctc atg gac gtc ctg tgg aag cag gag ggg ctg gac ctg agg atg acc Leu Met Asp Val Leu Trp Lys Gln Glu Gly Leu Asp Leu Arg Met Thr 800 805 810	2629
ccc tat ggc tgc ctc ccc acc ggg gac cgc aca ggc ctc att gag gtg Pro Tyr Gly Cys Leu Pro Thr Gly Asp Arg Thr Gly Leu Ile Glu Val 815 820 825	2677

WO 01/05958

PCT/US00/00525

gta ctc cgt tca gac acc atc gcc aac atc caa ctc aac aag agc aac Val Leu Arg Ser Asp Thr Ile Ala Asn Ile Gln Leu Asn Lys Ser Asn 830 835 840	2725
atg gca gcc aca gcc gcc ttc aac aag gat gcc ctg ctc aac tgg ctg Met Ala Ala Thr Ala Ala Phe Asn Lys Asp Ala Leu Leu Asn Trp Leu 845 850 855	2773
aag tcc aag aac ccg ggg gag gcc ctg gat cga gcc att gag gag ttc Lys Ser Lys Asn Pro Gly Glu Ala Leu Asp Arg Ala Ile Glu Glu Phe 860 865 870 875	2821
acc ctc tcc tgt gct ggc tat tgt gtg gcc aca tat gtg ctg ggc att Thr Leu Ser Cys Ala Gly Tyr Cys Val Ala Thr Tyr Val Leu Gly Ile 880 885 890	2869
ggc gat cgg cac agc gac aac atc atg atc cga gag agt ggg cag ctg Gly Asp Arg His Ser Asp Asn Ile Met Ile Arg Glu Ser Gly Gln Leu 895 900 905	2917
ttc cac att gat ttt ggc cac ttt ctg ggg aat ttc aag acc aag ttt Phe His Ile Asp Phe Gly His Phe Leu Gly Asn Phe Lys Thr Lys Phe 910 915 920	2965
gga atc aac cgc gag cgt gtc cca ttc atc ctc acc tac gac ttt gtc Gly Ile Asn Arg Glu Arg Val Pro Phe Ile Leu Thr Tyr Asp Phe Val 925 930 935	3013
cat gtg att cag cag ggg aag act aat aat agt gag aaa ttt gaa cgg His Val Ile Gln Gln Gly Lys Thr Asn Asn Ser Glu Lys Phe Glu Arg 940 945 950 955	3061
ttc cgg ggc tac tgt gaa agg gcc tac acc atc ctg cgg cgc cac ggg Phe Arg Gly Tyr Cys Glu Arg Ala Tyr Thr Ile Leu Arg Arg His Gly 960 965 970	3109
ctt ctc ttc ctc cac ctc ttt gcc ctg atg cgg gcg gca ggc ctg cct Leu Leu Phe Leu His Leu Phe Ala Leu Met Arg Ala Ala Gly Leu Pro 975 980 985	3157
gag ctc agc tgc tcc aaa gac atc cag tat ctc aag gac tcc ctg gca Glu Leu Ser Cys Ser Lys Asp Ile Gln Tyr Leu Lys Asp Ser Leu Ala 990 995 1000	3205
ctg ggg aaa aca gag gag gag gca ctg aag cac ttc cga gtg aag ttt Leu Gly Lys Thr Glu Glu Glu Ala Leu Lys His Phe Arg Val Lys Phe 1005 1010 1015	3253
aac gaa gcc ctc cgt gag agc tgg aaa acc aaa gtg aac tgg ctg gcc Asn Glu Ala Leu Arg Glu Ser Trp Lys Thr Lys Val Asn Trp Leu Ala 1020 1025 1030 1035	3301
cac aac gtg tcc aaa gac aac agg cag tag tggctcctcc cagccctggg His Asn Val Ser Lys Asp Asn Arg Gln 1040	3351
cccaagagga ggcggctgcg ggctcgtgggg accaagcaca ttggctcctaa aggggctgaa	3411
gagcctgaac tgcacctaac gggaaaagaac cgacatggct gccttttgtt tacactggtt	3471

WO 01/05958

PCT/US00/00525

atttatttat gacttgaaat agtttaagga gctaaacagc cataaacgga aacgcctcct 3531
 tcatgcagcg gcgggtgctgg gccccccgag gctgcacctg gctctcggct gaggattgtc 3591
 accccaagtc ttccagctgg tggatctggg ccagcaaag actgttctcc tcccagaggga 3651
 accttcttcc caggcctccc gccagactgc ctgggtcctg gcgcctggcg gtcacctggg 3711
 gcctactgtc cgacaggatg ccttgatcct cgtgcgaccc accctgtgta tcttccctag 3771
 actgagttct ggcagctccc cgaggcagcc ggggtaccct ctagattcag ggatgcttgc 3831
 tctccacttt tcaagtgggt cttgggtacg agaattc 3868

<210> 2
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 2
 tcccgcaatg ccaacct 17

<210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 3
 tgtggaagag cggctcatat t 21

<210> 4
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 4
 agctgctgtg gcaccgcgc 19

<210> 5
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 5
 gaaggtgaag gtcggagtc 19

WO 01/05958

PCT/US00/00525

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 6
gaagatggtg atgggatttc 20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<223> PCR Probe

<400> 7
caagcttccc gttctcagcc 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 8
cggccgctcg tgccgaattc 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 9
gcgcagctgg cagggctggg 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 10
aatgagtgtc atcccgccct 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

WO 01/05958

PCT/US00/00525

<223> Antisense Oligonucleotide

<400> 11
ggcagattaa agatgcttta 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 12
tggaatagtc caagaaagac 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 13
gatgacagtt gtcctctctg 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 14
ctgcgttggt acttcccaga 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 15
tcctgcgttg ttacttccca 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 16
gcacccctgcg ttgttacttc 20

WO 01/05958

PCT/US00/00525

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 17
ggggcatcct gcgttggtac

20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 18
cagggggcat cctgcgttgt

20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19
ccccagggg catcctgcgt

20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20
ccaccccagg gggcatcctg

20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21
agtccacccc agggggcatc

20

<210> 22
<211> 20
<212> DNA

WO 01/05958

PCT/US00/00525

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22

ggcagtccac cccagggggc

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23

agaccctgt gggcagcagg

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24

cggtgctcgt cctccagctc

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25

ggacgggcag gaagggtgc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26

gcggcacgtc cttggtggac

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

WO 01/05958

PCT/US00/00525

<400> 27
cggctgctcc agggaccaca 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28
ccccggtctt aagctgggtcc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29
ggaagctgaa gtctagcagc 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30
aattccccag aaagtggcca 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31
actgcctggt gtcttttgac 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32
actactgcct gttgtctttg 20

WO 01/05958

PCT/US00/00525

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33
gccactactg cctgttgtct 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34
ggagccacta ctgcctgttg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35
ggaggagcca ctactgcctg 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36
ctgggaggag ccactactgc 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37
gggctgggag gagccactac 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

WO 01/05958

PCT/US00/00525

<223> Antisense Oligonucleotide

<400> 38

ccagggctgg gaggagccac

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39

cctcctcttg ggcccagggc

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40

accaatgtgc ttggtcccca

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41

gtcggttctt tcccgttagg

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42

atgaaggagg cgtttccggt

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43

cagccgagag ccaggtgcag

20

WO 01/05958

PCT/US00/00525

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
cctcgggagg agaacagtct 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45
agtaggcacc aggtgaccgc 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46
agctgccaga actcagtcta 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47
accacttga aaagtggaga 20

Docket No.
RTSP-0234

#7

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Antisense Modulation of P13 Kinase P110 Delta Expression

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 6 January 2000 as United States Application No. or PCT International Application Number PCT/US00/00525 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/357,070

July 19, 1999

Patented

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Jane Massey Licata, Reg. No. 32,257
 Kathleen A. Tyrrell, Reg. No. 38,350
 Laura M. Plunkett, Reg. No. 45,015
 Bridget C. Sciamanna, Reg. No. 47,333

of the firm

Licata & Tyrrell
 66 E. Main Street
 Marlton, New Jersey 08053

Herb Boswell, Reg. No. 27,311
 Laurel Spear Bernstein, Reg. No. 37,280
 Robert S. Andrews, Reg. No. 44,508
 Neil S. Bartfeld, Reg. No. 39,901
 Kenneth H. Tarbet, Reg. No. 43,181
 Donna T. Ward, Reg. No. 48,271
 Matthew Grumbling, Reg. No. 44,427

of the firm

ISIS Pharmaceuticals, Inc.-Carlsbad Research Center
 2292 Faraday Avenue
 Carlsbad, California 92008

Send Correspondence to:



26259

PATENT TRADEMARK OFFICE

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

1-00 Full name of sole or first inventor

Brett P. Monia

Sole or first inventor's signature

Brett P. Monia

Date

5/22/02

Residence

La Costa, California CA

Citizenship

US

Post Office Address

7605 Nueva Castilla Way

La Costa, California 92009

2-00 Full name of second inventor, if any

Lex M. Cowser

Second inventor's signature

Lex M. Cowser

Date

5/15/02

Residence

San Mateo, California CA

Citizenship

US

Post Office Address

1299 Parrott Drive

San Mateo, California 94402